Company Snapshot: AICX  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Applied Imaging Corp. Names Carl Hull Vice President of Worldwide Marketing

    SANTA CLARA, Calif., Aug. 5 /PRNewswire/ -- Applied Imaging Corp.
(Nasdaq: AICX) today announced the appointment of Carl W. Hull as Vice
President of Worldwide Marketing for the Company.  As Vice President of
Worldwide Marketing, Mr. Hull will be responsible for all aspects of the
Company's marketing efforts, including the Company's fetal cell screening
program and established cytogenetics business.  Mr. Hull will report to Dr.
Jack Goldstein, President and Chief Executive Officer.
    Prior to joining the Company, Mr. Hull served as Vice President of
Marketing & Business Development for Ventana Medical Systems.  From 1982 to
1996, he served in various marketing and sales management positions at Abbott
Laboratories, including Vice President and General Manager of Abbott
Laboratories, Puerto Rico, Marketing Manager for Hematology Products, District
Sales Manager as well as Product Manager for several diagnostic product lines.
    "We are very pleased to have Carl on the Applied Imaging team.  Carl's
experience in marketing, sales and international operations will be of great
benefit to the Company during this period of growth," said Goldstein.
    Mr. Hull received his MBA from the University of Chicago and a B.A. in
Political Science and International Relations from Johns Hopkins University.
He currently resides in Tucson, Arizona.
    Applied Imaging Corporation develops, manufactures and markets automated
clinical analysis systems used by laboratories for the diagnosis of prenatal
and other genetic disorders.  The Company markets its products worldwide.
Applied Imaging is developing a proprietary prenatal test for screening of
genetic abnormalities by isolating fetal cells from a routine maternal sample.
This new test is designed to improve current prenatal screening techniques by
providing an accurate and cost effective procedure without the risk of
miscarriage associated with invasive prenatal testing.
    For additional information on Applied Imaging via fax, dial 800-PRO-INFO,
or 908-544-2850 outside of the U.S., code AICX.


SOURCE Applied Imaging Corp.




Back to Topback to top

CONTACT:
Donna C. Dickinson, Investor Relations of
Applied Imaging Corp., 408-562-0250; or general information, Ann
Trunko, or investors, Kate Rajeck, 415-986-1591, both of the
Financial Relations Board, for Applied Imaging